Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : John Pitera's Market Laboratory -- Ignore unavailable to you. Want to Upgrade?

To: John Pitera who wrote (4667)	9/21/2001 4:15:46 PM
From: peter n matzke	Read Replies (3) \| Respond to of 33421

John this question is addressed to market influence. Based upon no research just my memory of approximate numbers, a few years ago the NYSE had about 1500-2000 stocks which were about 75-80% of the total stock valuation between the NYSE, Nasdaq and the AMEX The Nasdaq had roughly 15,000 issues between the OTC and the BB i don't recall the breakdown but i'm guestimating that it was about 8000 and 7000 issues respectively. Here's the question, with the pounding that the Nasdaq has taken, i would expect that many of the 8000 OTC issues have come into problems with some of the capital and trading requirements. If there is a massive change in listings from OTC to BB how would this affect the market? and those that make the market? Perhaps some of the requirements have been modified to reduce the number of delistings, which would not necessarily be a good or bad thing. Seems to me that Nasdaq had a $2 limit for a stock which would certainly bring a number of stocks into that potential list. Has anyone looked into these types of issues? Have there been thousands of stocks delisted? thanks peter